It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

The rise in obesity rates across the United States has brought increased attention to treatments aimed at addressing the ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The Centers for Medicare and Medicaid Services proposed changes to reduce prescription drug costs for Medicare Advantage and ...

Insurers, including the state, might consider serving up exercise and cooking classes along with the prescription.

Researchers at Henry Ford Health, collaborating with WeightWatchers International, report that more than 40% of individuals ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.